# Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

> **NCT01246206** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Tacrolimus and Thymoglobulin

## Key facts

- **NCT ID:** NCT01246206
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2018-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01246206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01246206, "Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01246206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*